VTRS

Neutral

Viatris launches €650M 4.250% senior notes due 2033 offering

Viatris (VTRS) has announced the launch of a €650 million offering of 4.250% Senior Notes due 2033. The company signed an underwriting agreement with ...

TradingView 7 hours ago 0

Neutral

Viatris (VTRS) prices €650M 4.250% senior notes maturing 2033

Viatris Inc. has priced €650 million in 4.250% Senior Notes due 2033, with the offering expected to close on June 17, 2026. The notes are being sold u...

Stock Titan 7 hours ago 0

Neutral

Euro Bond Sale Might Change The Case For Investing In Viatris (VTRS)

Viatris Inc. recently issued €648.30 million in euro-denominated senior unsecured notes, adding to its capital structure. This move prompts an examina...

Simply Wall Street 10 hours ago 0

Neutral

[424B5] Viatris Inc Prospectus Supplement (Debt Securities)

Viatris Inc. is offering Euro-denominated senior unsecured notes, guaranteed by its subsidiaries Mylan Inc., Mylan II B.V., and Utah Acquisition Sub I...

Stock Titan 3 days ago 0

Bullish

Salesforce : Agentforce Life Sciences Selected by Viatris as Its Global Customer Engagement Platform

Salesforce announced that Viatris, a global healthcare company, has chosen Salesforce's Agentforce Life Sciences for Customer Engagement as its global...

www.marketscreener.com 1 week ago 0

Bullish

U.S. FDA accepts Viatris new drug application for fast-acting meloxicam for the treatment of moderate-to-severe acute pain

The U.S. FDA has accepted Viatris's new drug application (NDA) for a fast-acting meloxicam intended for the treatment of moderate-to-severe acute pain...

marketscreener.com 4 weeks ago 0

Bullish

FDA accepts Viatris application for fast-acting meloxicam

The FDA has accepted Viatris Inc.'s New Drug Application for MR-107A-02, a fast-acting meloxicam formulation for moderate-to-severe acute pain. This n...

Investing.com 4 weeks ago 0